scholarly journals Boron neutron capture therapy: Current status and future perspectives

2020 ◽  
Vol 40 (9) ◽  
pp. 406-421 ◽  
Author(s):  
Mayya Alexandrovna Dymova ◽  
Sergey Yurjevich Taskaev ◽  
Vladimir Alexandrovich Richter ◽  
Elena Vladimirovna Kuligina
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Current Status ◽  
Neutron Capture Therapy ◽  
Future Perspectives ◽  
Boron Neutron Capture

scholarly journals Cover Image: Boron neutron capture therapy: Current status and future perspectives

2020 ◽  
Vol 40 (9) ◽  
Author(s):  
Mayya Alexandrovna Dymova ◽  
Sergey Yurjevich Taskaev ◽  
Vladimir Alexandrovich Richter ◽  
Elena Vladimirovna Kuligina
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Cover Image ◽  
Current Status ◽  
Neutron Capture Therapy ◽  
Future Perspectives ◽  
Boron Neutron Capture

scholarly journals Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects

2005 ◽  
Vol 11 (11) ◽  
pp. 3987-4002 ◽  
Author(s):  
Rolf F. Barth ◽  
Jeffrey A. Coderre ◽  
M. Graça H. Vicente ◽  
Thomas E. Blue
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Current Status ◽  
Neutron Capture Therapy ◽  
Future Prospects ◽  
Boron Neutron Capture

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Sign in / Sign up

Export Citation Format

Share Document